Oropharyngeal cancer related to Human Papilloma Virus: incidence and prognosis in Madrid, Spain

Cerezo, Laura; Torre, Alejandro de la; Hervás, A.; Ruíz, A.; Liñan, O.; López, Mauricio; Villar, Karen; Martín, Marta

doi:10.1007/s12094-013-1074-5

Cited by 10 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the vast majority of included studies were retrospective cohorts, and the inherent limitations of retrospective designs should be taken into consideration, the collection of data did occur prospectively in all but 2 studies. 1,38 None of the other studies were found to have methodologic flaws that would call into question the study findings. Refer to Supplemental Table 3 in the supplemental digital content for the quality assessment results for all studies included in the statement 2 evidentiary base.…”

Section: Resultsmentioning

confidence: 93%

Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists

Lewis

Beadle

Bishop

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

440

498

View full text Add to dashboard Cite

Context Human papillomavirus (HPV) is a major cause of oropharyngeal squamous cell carcinomas, and HPV (and/or surrogate marker p16) status has emerged as a prognostic marker that significantly impacts clinical management. There is no current consensus on when to test oropharyngeal squamous cell carcinomas for HPV/p16 or on which tests to choose. Objective To develop evidence-based recommendations for the testing, application, interpretation, and reporting of HPV and surrogate marker tests in head and neck carcinomas. Design The College of American Pathologists convened a panel of experts in head and neck and molecular pathology, as well as surgical, medical, and radiation oncology, to develop recommendations. A systematic review of the literature was conducted to address 6 key questions. Final recommendations were derived from strength of evidence, open comment period feedback, and expert panel consensus. Results The major recommendations include (1) testing newly diagnosed oropharyngeal squamous cell carcinoma patients for high-risk HPV, either from the primary tumor or from cervical nodal metastases, using p16 immunohistochemistry with a 70% nuclear and cytoplasmic staining cutoff, and (2) not routinely testing nonsquamous oropharyngeal carcinomas or nonoropharyngeal carcinomas for HPV. Pathologists are to report tumors as HPV positive or p16 positive. Guidelines are provided for testing cytologic samples and handling of locoregional and distant recurrence specimens. Conclusions Based on the systematic review and on expert panel consensus, high-risk HPV testing is recommended for all new oropharyngeal squamous cell carcinoma patients, but not routinely recommended for other head and neck carcinomas.

show abstract

Section: Resultsmentioning

confidence: 93%

Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists

Lewis

Beadle

Bishop

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

440

498

View full text Add to dashboard Cite

show abstract

“…In total, 64 articles were included in the analysis, with a total of 11710 patients in these studies. The number of patients varied between 30 and 1474 (mean 202 patients per study) ( Table 1 ) [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] . ...…”

Section: Resultsmentioning

confidence: 99%

Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years

Haeggblom

Ramqvist

Tommasino

et al. 2017

Papillomavirus Research

View full text Add to dashboard Cite

ObjectivesHuman papillomavirus (HPV) as a risk factor in oropharyngeal squamous cell carcinoma (OPSCC) is well established. However, accumulating data imply that the OPSCC concept is too unspecific with regard to HPV prevalence and clinical importance. To further study the role of HPV in OPSCC by sub-site, a systematic review and meta-analysis was performed.Material and methodPubMed was searched and all studies reporting HPV data (p16/HPV DNA/RNA) in both “lymphoepithelial associated” (i.e. tonsillar and base of tongue cancer; TSCC and BOTSCC respectively) and “non-lymphoepithelial” (“other” OPSCC) OPSCC were included. Pooled odds ratios by HPV detection method were analysed using a random effects model.ResultsIn total, 58 unique patient cohorts were identified. Total HPV prevalence in TSCC/BOTSCC was 56%, 95%CI: 55–57% (59%, 95%CI: 58–60% for TSCC only) as compared to 19%, 95%CI: 17–20%, in “other” OPSCC. Significant association of HPV to TSCC/BOTSCC vs. “other” OPSCC was observed no matter HPV detection method used, but statistical homogeneity was only observed when studies using algorithm based HPV detection were pooled.ConclusionHPV prevalence differs markedly between OPSCC sub-sites and while the role of HPV in TSCC/BOTSCC is strong, the role in “other” OPSCC is more uncertain and needs further evaluation.

show abstract

“…Nevertheless, the epidemiology of the disease in southern Europe, where current estimates of HPV prevalence are low (9–24%) 2 , 10 , has not been extensively investigated. In Spain, only two studies on HPV involvement in selected OPC cases were available 11 , 12 until our group recently reported the results of a multicenter retrospective cohort of 788 patients with primary OPC consecutively diagnosed between 1991 and 2013 13 . The study identified double positivity for HPV-DNA/p16 INK4a as the biomarker with strongest diagnostic accuracy and prognostic value for HPV-related OPC patients and found an HPV prevalence of 7.4% when considering HPV-DNA/p16 INK4a double positivity 13 .…”

Section: Introductionmentioning

confidence: 99%

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe

Mena

Frias-Gomez

Cequier

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The incidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing in some regions. Nevertheless, the epidemiology of this disease has not been extensively investigated in southern europe. We conducted a retrospective cohort study of patients diagnosed with primary oropharyngeal cancer from 1991 to 2016. Cancer tissues underwent histopathological evaluation, DNA quality control, HPV-DNA detection and p16 INK4a immunohistochemistry. Data were collected from medical records. Factors associated with HPV positivity and time trends were evaluated with multivariable Bayesian models. The adjusted prevalence of HPV-related cases in 864 patients with a valid HPV-DNA result was 9.7%, with HPV-DNA/p16 INK4a double positivity being considered. HPVrelated oropharyngeal cancer was likely to occur in non-smokers and non-drinkers, to be located in the tonsil or diagnosed at advanced stages. Time-trend analysis showed an increasing risk of HPV-related oropharyngeal cancer in the most recent periods (5-year period increase of 30%). This increase was highest and with a clear increasing trend only in the most recent years (2012-2016). The prevalence of HPV-related oropharyngeal cancer started to sharply increase in the most recent years in our setting,

show abstract

Oropharyngeal cancer related to Human Papilloma Virus: incidence and prognosis in Madrid, Spain

Abstract: Incidence of HPV-related OC in our region is similar to that reported in other regions in Europe, yet lower than in North America. We observed a trend for improved OS in patients with HPV+ oropharyngeal cancer.

Cited by 10 publications

References 23 publications

Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists

Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists

Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe

Contact Info

Product

Resources

About